Loading organizations...
Phil has raised $176.0M across 6 funding rounds.
Key people at Phil.
Phil has raised $176.0M in total across 6 funding rounds.
Phil develops a technology platform streamlining medication access and commercialization for retail and specialty-lite pharmaceutical brands. Its digital hub provides direct-to-patient capabilities, enhancing access, adherence, covered dispenses, and gross-to-net outcomes. The platform integrates modern patient and provider experiences, advanced prior authorization, and an integrated pharmacy network, simplifying the prescription journey.
Co-founded in 2015 by Deepak Thomas and Puran Singh, Phil originated from the insight that seamless prescription access is vital for patient health. Identifying inefficiencies in traditional medication access, they built a technology solution. Their expertise underpins the platform, addressing systemic complexities for patients, providers, and manufacturers.
Phil primarily serves pharmaceutical manufacturers, enhancing patient and provider brand experiences. Patients gain easier PhilRx access, while providers use efficient prescribing and prior authorization tools. The company’s vision centers on improving patients' lives through technology, delivering exceptional experiences and driving partner success by transforming life sciences access.
Phil has raised $176.0M in total across 6 funding rounds.
Phil's investors include Austin Sherwindt, Fred Hassan, Andreessen Horowitz, Bessemer Venture Partners, NextView Ventures, One Planet Group, Uncork Capital, Steven Sarowitz, Andrew Perlman, 11, Accel, Addition.
# Phil: Revolutionizing Pharmaceutical Access Through Technology
Phil (PhilRx) is a pharma-tech platform that helps pharmaceutical manufacturers streamline patient access, provider engagement, and medication dispensing through software-driven solutions[1][3]. Founded in 2015 and headquartered in Scottsdale, Arizona, the company operates a digital hub platform that integrates with a national dispense network to create a seamless experience across the drug supply chain[1][3].
The company serves three primary stakeholders: pharmaceutical manufacturers seeking to maximize brand value and market reach, healthcare providers needing efficient prescription management, and patients requiring convenient access to medications[2][5]. Phil's core mission centers on improving patient outcomes by removing friction from the medication access journey—addressing a critical pain point in healthcare where complex prior authorization processes, insurance barriers, and logistical challenges often delay or prevent patients from obtaining prescribed therapies[2][3].
Phil was founded in 2015 by Deepak Thomas, who continues to serve as CEO[1]. The company emerged during a period of growing recognition that traditional pharmaceutical access infrastructure was outdated and inefficient. Rather than relying on legacy systems and manual processes, Phil built a modern, technology-first alternative designed to give pharmaceutical brands real-time visibility into their drug channels while simultaneously improving the patient experience[3][4].
The company has demonstrated significant traction, raising $141 million across three funding rounds, reflecting investor confidence in the pharma-tech sector and Phil's execution[1]. This capital has enabled expansion from its Arizona headquarters to a substantial presence in San Francisco, with a team of 51–200 employees[1].
Phil operates at the intersection of healthcare digitization and pharmaceutical commercialization—two sectors experiencing accelerating transformation. The company rides several powerful trends: the shift toward value-based care, increasing regulatory pressure on drug pricing and access, and the broader adoption of software-as-a-service models in traditionally analog industries[2][3].
The timing is particularly favorable. Healthcare systems and pharmaceutical manufacturers face mounting pressure to demonstrate patient outcomes and cost efficiency. Simultaneously, digital health adoption has normalized direct-to-patient engagement models. Phil's platform captures this moment by offering manufacturers a modern alternative to decades-old access infrastructure, effectively modernizing a critical but overlooked segment of the healthcare value chain[3][4].
By improving patient access and adherence at scale, Phil influences the broader ecosystem by reducing barriers between patients and life-saving medications—a challenge that affects millions annually and represents a significant drag on pharmaceutical ROI.
Phil is well-positioned to become the dominant software platform for pharmaceutical access and commercialization as the industry continues its digital transformation. The company's $141 million in funding and growing team suggest momentum toward either significant scale or acquisition by a larger healthcare technology or pharmaceutical services company.
The future likely involves deeper integration with healthcare provider systems, expanded direct-to-patient capabilities, and potentially AI-driven optimization of access pathways—trends that align with broader healthcare automation. As regulatory scrutiny on drug pricing intensifies and manufacturers seek competitive advantages through superior patient outcomes, platforms like Phil that combine access, visibility, and engagement will become increasingly essential infrastructure rather than optional tools.
Key people at Phil.
Phil has raised $176.0M across 6 funding rounds. Most recently, it raised $60.0M Debt in July 2025.